Short Interest in Kamada Ltd. (NASDAQ:KMDA) Grows By 33.3%

Posted by Suzanne Cooper on Feb 1st, 2025

Kamada Ltd. (NASDAQ:KMDA – Get Free Report) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 23,200 shares, an increase of 33.3% from the December 31st total of 17,400 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 63,600 shares, the days-to-cover ratio is presently 0.4 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Kamada in a report on Friday, January 10th.

View Our Latest Stock Report on Kamada

Institutional Investors Weigh In On Kamada

An institutional investor recently bought a new position in Kamada stock. Public Employees Retirement System of Ohio acquired a new position in Kamada Ltd. (NASDAQ:KMDA – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 14,270 shares of the biotechnology company’s stock, valued at approximately $77,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Stock Up 0.3 %

KMDA stock traded up $0.02 during trading on Friday, reaching $6.73. The stock had a trading volume of 45,552 shares, compared to its average volume of 154,608. The company has a market capitalization of $386.84 million, a price-to-earnings ratio of 24.04, a P/E/G ratio of 0.86 and a beta of 0.98. The company’s 50 day moving average is $6.42 and its two-hundred day moving average is $5.86. Kamada has a one year low of $4.74 and a one year high of $8.00.

About Kamada

(Get Free Report)

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.